Reasons to Retain TransMedics Stock in Your Portfolio for Now

TransMedics Group, Inc. (TMDX) is well-poised for growth in the coming quarters, courtesy of its strength in OCS technology. The optimism, led by solid first-quarter 2025 results, is expected to contribute further. However, concerns due to gross margin pressure and U.S transplant volume headwinds persist.This Zacks Rank #3 (Hold) company has gained 97.8% in the year-to-date period against a 9.9% decline of the industry. The S&P 500 has declined 1.2% in the said time frame.The renowned organ transplant thera ...